Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 5,280 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 5,280 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $48.91, for a total transaction of $258,244.80. Following the completion of the sale, the chief executive officer directly owned 96,200 shares in the company, valued at approximately $4,705,142. The trade was a 5.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total value of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.42, for a total value of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total value of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total value of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total value of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total value of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.47, for a total transaction of $400,600.20.

Phibro Animal Health Stock Performance

PAHC opened at $51.17 on Tuesday. The firm has a fifty day moving average price of $46.57 and a 200 day moving average price of $42.40. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $56.30. The stock has a market cap of $2.07 billion, a P/E ratio of 22.74, a P/E/G ratio of 0.76 and a beta of 0.73. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.69 by $0.18. The company had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s payout ratio is currently 21.33%.

Institutional Trading of Phibro Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of the business. 1620 Investment Advisors Inc. lifted its position in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after buying an additional 295 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after acquiring an additional 386 shares during the last quarter. Rothschild Investment LLC increased its position in shares of Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after acquiring an additional 1,000 shares during the last quarter. Hughes Financial Services LLC purchased a new stake in shares of Phibro Animal Health in the 3rd quarter valued at approximately $40,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Phibro Animal Health in the 3rd quarter valued at approximately $61,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Phibro Animal Health currently has an average rating of “Moderate Buy” and an average price target of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.